.webp?width=901&height=1200&name=Mounjaro%20Image%20900x1200%20(without%20notification).webp)
Mounjaro® (tirzepatide) is FDA-approved to treat type 2 diabetes. According to SURPASS-2 clinical trials, it has shown to be very effective in treating type 2 diabetes, especially compared to other drugs on the market, such as semaglutide. It has also shown to be an effective alternative option when other medications, including Janumet, do not provide sufficient glycemic control.
Although Mounjaro® is not FDA-approved for weight loss, it has been found to cause significant weight loss. Tirzepatide for weight loss is now available under the brand name Zepbound®. Based on the SURMOUNT-1 clinical trial results, Zepbound® will likely become the most effective weight loss drug available.
While Mounjaro® (tirzepatide) is an excellent option for many, we believe in shedding light on alternative medications, ensuring accessibility to the most fitting treatment. Considering availability and individual preferences, our physicians may propose or prescribe another GLP-1 for effective type 2 diabetes management. Here's a glance at these GLP-1 options:
-
Compounded tirzepatide: In light of current shortages, compounded tirzepatide may be prescribed as an alternative to branded Mounjaro® as long as Mounjaro remains on the FDA drug shortages list. While compounded tirzepatide is not FDA-approved, our preferred pharmacy provider adheres to all relevant federal and state regulations and FDA guidelines.*
Other medication treatment options:
-
Ozempic® (semaglutide): Ozempic® comes in a once-weekly injectable format. Beyond reliability and efficiency in blood sugar management, it offers the added benefit of reducing cardiovascular risk, enhancing its appeal.
-
Semaglutide: Due to shortages, compounded semaglutide may be prescribed as an alternative to branded Ozempic® as long as it remains on the FDA drug shortages list. Although compounded semaglutide is not FDA-approved, our pharmacy provider complies with pertinent federal and state laws and FDA regulations.*
-
Rybelsus® (semaglutide): Rybelsus® is an oral GLP-1 medication, ideal for those favoring a pill over injections. However, injectable semaglutide has a higher range of doses for those who need benefits beyond what oral semaglutide can provide.
-
Trulicity® (dulaglutide): Recognized for its user-friendly design, Trulicity® offers a once-weekly injection experience with a pre-filled, disposable pen.
-
Victoza® (liraglutide): Victoza® is a daily injectable for diabetes management. Its daily regimen suits individuals looking for a consistent, day-to-day approach to their treatment.
-
Bydureon® (exenatide): Bydureon® provides another option for once-a-week injection treatment.
*Availability for compounded semaglutide and tirzepatide is limited to residents in the following states:
Compounded Semaglutide: AZ, CA, CO, DE, FL, GA, HI, IA, ID, IL, KS, MA, MD, ME, MO, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SD, TN, TX, UT, VA, WA, WV, Washington D.C., WY.
Compounded Tirzepatide: AZ, CA, CO, DE, FL, GA, HI, IA, ID, IL, KS, MA, MD, ME, MO, MT, NC, ND, NE, NH, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SD, TN, TX, UT, VA, WA, WV, Washington D.C., WY.
Although compounded semaglutide and tirzepatide are not FDA-approved, our pharmacy provider complies with all federal and state laws and FDA regulations.
